(Revised) Next Day Disclosure Return
Filed with HKEX · Stock code 2096 ·
6ix hasn’t read this filing yet.
Simcere Pharmaceutical Group Limited on 6ix
Earlier from Simcere Pharmaceutical
- Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
- Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
- Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
- Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
- NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
Later from Simcere Pharmaceutical
- 2026 Interim report
- Notification letter and reply form to registered shareholders: notice of publication of interim report 2026
- Notification letter and reply form to non-registered holders: notice of publication of interim report 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Next Day Disclosure Return
Follow Simcere Pharmaceutical into a list and get an email when it puts out news.
Follow Simcere Pharmaceutical